Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.61 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27633486 | 0.91 | ALDH1A1 (0.65) | ALDH1A1HPGDPTGS1PTGS2PIN1 | |
| SCHEMBL14692202 | 0.87 | PTGS2 (0.63) | ALDH1A1HPGDPTGS1PTGS2 | |
| SCHEMBL20376677 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDPTGS1PTGS2 | |
| SCHEMBL6495602 | 0.82 | ALDH1A1 (0.55) | ALDH1A1HPGDPTGS1PTGS2CYP1A2 | |
| SCHEMBL5762947 | 0.77 | KDM4E (0.62) | ALDH1A1HPGDPIN1CYP1A2MAPK1 | |
| SCHEMBL6503776 | 0.75 | PIN1 (0.50) | ALDH1A1HPGDPIN1CYP1A2MAPK1 | |
| SCHEMBL4879884 | 0.74 | KDM4E (0.59) | ALDH1A1HPGDPIN1CYP1A2MAPK1 | |
| SCHEMBL5762937 | 0.73 | PIN1 (0.49) | ALDH1A1HPGDPIN1CYP1A2MAPK1 | |
| SCHEMBL4802255 | 0.73 | SMN1; SMN2 (0.49) | ALDH1A1HPGDPIN1CYP1A2MAPK1 | |
| SCHEMBL5820825 | 0.73 | KDM4E (0.66) | ALDH1A1HPGDPTGS1PTGS2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641765-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-04-05 | — | — | EP | disclosed |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108685-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AHR, ARNT, MYC | ALDH1A1 240/4885HPGD 664/4885PTGS1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.